Lexicon Pharmaceuticals (NASDAQ: LXRX) shares are trading sharply higher after the company announced it received FDA regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new drug application submission.
Lexicon is a biopharmaceutical company developing medicines that transform patients’ lives. The company commercializes and develops drugs and drug candidates.
Lexicon’s stock was trading higher by 102% to $7.92 at the time of publciaiton.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.